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The present investigation was undertaken in order to determine the in vivo plasma protein binding 
of furosemide in kidney transplant patients and its possible consequence on furosemide effect. 
Using an equilibrium dialysis technique, serial plasma samples of furosemide taken after 
intravenous administration were dialyzed against an equal volume of isotonic Krebs Ringer 
bicarbonate buffer (pH 7.4). Dialysis was performed at 3 7~ for 5 hr, and furosemide concentra- 
tions (total as well as free) were analyzed by HPLC using fluorescence detection. It was observed 
that kidney transplant patients on concomitant sulfisoxazole treatment (KT+) had a 
significantly greater value for percent free of furosemide as compared to transplant patients not 
on sulfisoxazole ( K T - )  (4.44-0.8 for KT+ vs. 1.74-0.3% for K T - ;  p<O.01) as well as to 
healthy volunteers (4.4 4- 0.8 for K T  + vs. 1.2+0.2% for controls; p < O.01). In addition, kidney 
transplant patients not on concomitant sulfisoxazole treatment had a significantly higher value 
for percent free of furosemide with respect to healthy volunteers (p ~ 0.05). Nonlinear plasma 
protein binding was also observed for one patient, who had values for percent free of fumsemide 
ranging from 1.3 to 12.9%. However, no significant correlation was found between the fraction 
of the dose excreted unchanged in the urine and percent free of furosemide. 
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I N T R O D U C T I O N  
It is generally recognized that the binding of a drug to plasma proteins 
can affect its distribution, elimination, and ultimately its therapeutic or 
toxic response since only the unbound drug is pharmacologically active. It 
has also been established that renal impairment may alter drug binding to 
plasma proteins (1-5), particularly with respect to acidic drugs (3). Possible 
explanations for reduced drug binding in patients with renal dysfunction 
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include hypoalbuminemia (2), the presence of irreversible and competitive 
inhibitors in the plasma (3,5), and altered albumin composition (1). 
Furosemide is a valuable diuretic in kidney transplant patients for the 
treatment of volume overload. It is highly bound to plasma proteins (6-12) 
and gains access to its site of action in the kidney lumen primarily through 
active secretion via the nonspecific organic acid secretory pathway (13-15). 
Previous studies have shown that renal disease can effect dramatic changes 
in the pharmacokinetics of furosemide (6,11,16-20), including impaired 
plasma protein binding in uremics (7,11), nephrotics (10,11), and anephric 
patients (6). The degree of binding of furosemide to plasma proteins in 
kidney transplant patients has not been reported. Since only the free drug 
is presumed to be transported by the kidney into the tubular fluid, it may 
be important to understand the role of plasma protein binding with respect 
to the natriuretic and diuretic response to furosemide. 
METHODS 
Patient Studies 
The characteristics of nine kidney transplant patients were previously 
described and the pharmacokinetics and pharmacodynamics of furosemide 
in this patient population were evaluated (19). Patients were titrated to, 
and studied at, a dose capable of inducing an adequate pharmacodynamic 
response. In addition, transplant patients were subdivided into responder 
(R; 40-80 mg/day) and nonresponder (NR; >/120 mg/day) populations as 
previously described (19). 
After fasting overnight, the intravenous dose of furosemide was infused 
over a 10 min period at approximately 8 a.m. Blood samples (3 ml) were 
obtained from an indwelling heparinized scalp vein needle at 0, 10, 15, 
20, 30, 45, 60, 80, 100; 120, 180, 240, 360, 480, and 1440 rain; the end 
of the infusion period being 10 min. All patients signed the consent form 
approved by the Human Research Committee of the University of 
California, San Francisco. 
Measurement of Furosemide 
Plasma samples were assayed for total furosemide (bound and free) 
by a high performance liquid chromatographic method as described by 
Smith et al. (19). The analytical procedure for determination of free 
furosemide concentrations in dialyzed buffer has also been previously 
reported (12). However, chlorpromazine hydrochloride (0.02%) was sub- 
stituted as the internal standard for the analysis of furosemide in those 
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patients concomitantly taking sulfisoxazole (19). This was necessary since 
sodium phenobarbital, our usual internal standard for furosemide, and 
sulfisoxazole have similar retention times and will interfere with each other. 
Protein Binding 
The in vivo binding of furosemide to plasma proteins was determined 
using an equilibrium dialysis method (12). One-half ml of plasma was 
dialyzed against an equal volume of isotonic Krebs Ringer bicarbonate 
buffer (pH 7.4). Dialysis was performed at 37~ for 5 hr using Spectrapor 
2 membrane tubing (Spectrum Medical Industries, Inc., Los Angeles, 
Calif.). 
Calculations 
The percent free or percent of furosemide unbound to plasma proteins 
(fu) was calculated as 
fu = 100 x Cf' / (Cp - Cf') (1) 
where Cp represents the measured total plasma concentration of 
furosemide prior to dialysis and Cf' represents the measured unbound or 
free concentration of furosemide in buffer after dialysis. Equation (1) 
assumes that the initial plasma and buffer volumes are equal prior to 
dialysis, that there is negligible binding of drug to the dialysis membrane, 
and that protein binding is linear. In cases of nonlinear plasma protein 
binding, equation (1) is inappropriate and will underestimate the true value 
for the percent free of drug in the original plasma sample. Patient EH 
displayed nonlinear binding of furosemide to plasma proteins and values 
for percent free were determined, in this patient accordingly (21,22). 
The appropriate bound (Cb") and free (Cf') equilibrium concentrations 
of furosemide were best fitted to a conventional protein binding model for 
a single Langmuir term plus a linear term: 
Cb"= PI . Cf ' / (P2  + Cf') + P 3 .  Cf' (2) 
where Cb" represents the concentration of bound drug in the plasma 
compartment at dialysis equilibrium assuming no volume change (a 
hypothetical concentration which cannot be measured). This representation 
is necessary in order to correct for the osmotic water shift that occurs 
(10-15% for furosemide) during equilibrium dialysis, resulting in lower 
protein and drug concentrations in the postdialysis plasma compartment 
(22). Other protein binding models were tested (single Langmuir and double 
Langmuir), but the data did not fit them as well, as determined by the 
values for the coefficient of determination and the residual sum of squares. 
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Since the initial volumes of the plasma and buffer compartments were 
equal prior to dialysis, Cb" was calculated (22) and is given by Eq. (3): 
Cb" = Cp - 2 .  Of'  (3) 
where Cp and Cf'  were experimentally determined. The above Langmuir- 
type protein binding model (Eq. 2) can be modified (21) to give the quadratic 
equation given by Eq. (4): 
( 1 + P 3 )  9 Cf2+(pI+P2+P2 9 P 3 - C p ) .  C f - P 2 .  Cp = 0  (4) 
where the binding parameters P1, P2, and P3 were obtained from a 
computer fit to the Langmuir-type model (Eq. 2). Values for the free 
plasma concentrations of furosemide prior to dialysis or in the original 
plasma sample (Cf) were obtained by finding the positive root of the 
quadratic equation (4) for a given value of Cp. 
The percent free of drug in the original plasma sample ( fu)  can now 
be calculated using Eq. (5): 
fu = 100 x Cf/Cp (5) 
The above equations were used for patient EH, who demonstrated non- 
linear binding of furosemide to plasma proteins. Values for percent free 
of furosemide in plasma for all other kidney transplant patients were 
determined using Eq. (1). 
RESULTS 
The plasma protein binding of furosemide in kidney transplant patients 
is presented in Table I. Serial plasma samples taken after intravenous 
administration ranged from 0.32 to 124 tzg/ml total furosemide. The varia- 
bility between patients in percent free of furosemide was substantial as 
evidenced by an approximate 50% coefficient of variation. 
Patient EH demonstrated nonlinear protein binding as displayed in 
Fig. 1. The appropriate bound and free equilibrium plasma concentrations 
were fitted to Eq. (2) by nonlinear least squares using the "Multi-fun" 
procedure of Prophet (a specialized computer resource developed by the 
Chemical/Biological Information Handling Program of the National 
Institutes of Health). The parameters obtained by computer fitting were 
P1 =4.02, P2 = 0.0525, and P3 = 4.54 (r 2 = 0.980). Using the above 
parameters, and the original total plasma concentrations, the corresponding 
free concentrations of furosemide were estimated and appropriate values 
for percent free were obtained. Patient EH had an approximate 10-fold 
range in percent free over the total furosemide plasma concentrations 
studied (Fig. 2). 
Table I. Plasma Protein Binding of i.v. Furosemide in Kidney Transplant Patients 
Serum 
Treatment albumin conc. Percent ~ C V  
Patient Status (mg i.v.) (gm %) free SD b (%) 
CT NR 160 4.4 1.6 0.3 18.8 
EH NR 120 3.4 1.3_12.9 c c 
DH NR 120 4.2 1.6 0.2 12.5 
LT NR 120 3.9 2.2 0.1 4.6 
VW R 80 4.4 a d 
SJ R 120 4.1 5.2 2.2 42.3 
PD R 40 3.7 3.7 1.2 32.4 
WJ R 80 4.5 1.5 0.1 6.7 
FR R 80 3.5 4.2 1.4 33.3 
Intersubject variability: 2.9 • 1.5 








~The percent free for each patient represents the mean value for at least eight serial plasma 
samples taken after i.v. administration. 
bIntrasubject variability. 
CThe range of values for percent free in patient EH are reported due to nonlinear plasma 
~rotein binding. These values were excluded from the intersubject variability results~ 
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Fig. 1. Relationship between bound and free equilibrium plasma concentrations 
of furosemide in kidney transplant patient EH. 
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Fig. 2. Relationship between percent free and total 
furosemide plasma concentrations in kidney transplant 
patient EH. 
Tab le  I I  c o m p a r e s  the  values  for  pe r cen t  f ree  of fu rosemide  b e t w e e n  
hea l thy  vo lun tee r s  (controls) ,  k idney  t r ansp lan t  pa t i en t s  not  t ak ing  
sulf isoxazole  concomi t an t l y  ( K T - )  and  t r ansp l an t  pa t i en t s  t ak ing  
sulf isoxazole  concomi t an t l y  ( K T + )  with fu rosemide .  The  resul ts  d e m o n -  
s t ra te  tha t  those  k idney  t r ansp lan t  pa t i en t s  who are  on concomi t an t  
sulf isoxazole  t r e a t m e n t  have  a s ignif icant ly g rea t e r  pe r c e n t  f ree  of 
f u ro semide  as c o m p a r e d  to  t r ansp lan t  pa t i en t s  not  on sulf isoxazole  (4.4 + 
0.8 for  K T +  vs. 1 . 7 + 0 . 3 %  for K T - ;  p < 0 . 0 1 )  as well  as to hea l thy  
Table II. Comparison of Plasma Protein Binding of i.v. Furosemide in Healthy 
Volunteers and Kidney Transplant Patients 
Controls ~ K T -  b KT + ~ 
(n = 9) (n = 4) (n = 3) 
Percent free 1.2 1.7 4.4 
SD 0.2 0.3 0.8 
9 9 d Level of slgmficance (p < 0.01) 
Comparison Inference e 
KT+ vs. controls p < 0.01 
KT+ vs. K T -  p <0.01 
KT-  vs. controls p < 0.05 
~Values were previously reported (12). 
bKidney transplant patients not concomitantly taking sulfisoxazole. 
c Kidney transplant patients concomitantly taking sulfisoxazole. 
dDetermined by single factor analysis of variance. 
eLevel of significance determined by Newman-Keuls multiple range test. 
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volunteers (4.4+0.8 for KT+ vs. 1.2+0.2% for controls; p <0.01). In 
addition, kidney transplant patients not on concomitant sulfisoxazole treat- 
ment had a significantly higher value for percent free of furosemide with 
respect to healthy volunteers (1.7 + 0.3 for K T -  vs. 1.2 + 0.2% for controls; 
p < 0.05). 
DISCUSSION 
Impaired binding of furosemide to plasma proteins has been reported 
in uremics (7,11), nephrotics (10-11), and anephric patients (6). In the 
present study, the percent free of furosemide in plasma was significantly 
greater in kidney transplant patients ( K T -  and KT+)  than in healthy 
volunteers. This was probably due to the presence of endogenous and 
exogenous (drugs) substances which compete with furosemide for binding 
sites on the plasma proteins. Since furosemide is exclusively bound to 
albumin (7,10), the presence of hypoalbuminemia has been postulated (11) 
as a possible cause for reduced drug binding of furosemide in patients with 
renal dysfunction. However, the kidney transplant patients in this study 
were normal with respect to serum albumin levels, and no significant 
correlation was observed between percent free of furosemide and albumin 
concentration (Fig. 3). This lack of correlation was in agreement with results 
from a previous study in anephric patients (6). Nevertheless, it should be 
noted that the lack of correlation between percent free of furosemide and 
albumin concentration may have been obscured by the inhomogenous 
patient population studied (3 out of the 7 patients were receiving concom- 
itant sulfisoxazole therapy). 
Although the mean values for percent free were two-fold greater in 
responder than in nonresponder kidney transplant patients, the difference 
was not statistically significant (3.6+1.6 for R vs. 1.8+0.3% for NR; 
p > 0.10). This was due to the large variability in this parameter between 
responders (CV = 44.4%) and probably reflects the effect of concomitant 
sulfisoxazole administration in three out of the four patients studied in this 
population. The effect of sulfisoxazole on furosemide protein binding was 
assessed by comparing the percent free of those patients concomitantly 
taking sulfisoxazole with those patients on furosemide without sulfisoxazole 
(Table II). Not only were these two groups (KT-  and KT + ) different from 
one another with respect to percent free, but their within group variability 
(CV = 17.6% for K T -  ; C V  = 18.2% for KT+)  was substantially reduced, 
compared to the total transplant population, and in good agreement with 
the variability observed for percent free in healthy volunteers (CV = 
16.7 %). This displacing effect by sulfisoxazole has previously been demon- 
strated in vitro and results in significantly reduced binding of furosemide 
to human albumin (10). 
















SERUM ALBUMIN (GM%) 
Fig. 3. Correlation between percent free of furosemide in 
plasma and albumin concentration in kidney transplant 
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Fig. 4. Correlation between the corrected renal clearance of furosemide (CLr/CLcr) 
and percent free in plasma in kidney transplant patients (r = 0.762, p < 0.05). 
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Table IIL Incremental Renal Clearances for Patient EH a 
Time ACp Percent free CLr 
(min) (/xg/ml) (ml/min) 
0-40 7.5-13.6 9.1-12.9 18.5 
40-94 3.8-7.5 3,9-9.1 33,9 
94-130 2.6-3.8 2.5-3.9 29.6 
130-208 1.6-2.6 1,8-2.5 18.9 
208-328 0.8-1.6 1.5-1.8 14,5 
328-480 0.3-0.8 1.3-1.5 16.9 
aDetermined following 120mg intravenous dose of 
furosemide. ACp represents the range of total plasma con- 
centrations of furosemide during the specified time interval. 
CLr represents the incremental renal clearance. 
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A positive correlation was observed in kidney transplant patients 
between the corrected renal clearance of furosemide (CLr/CLcr) and the 
percent free in plasma (Fig. 4; r = 0.762, p < 0.05). This finding is consistent 
with a study by Yacobi and Levy (23) who found the renal clearance of 
sulfisoxazole in rats to be positively correlated with the serum free fraction 
of the drug. In addition, Table III reveals that, except for the initial 
collection interval (0-40 rain), a significant positive correlation exists 
between the median percent free and the incremental renal clearance of 
furosemide in patient EH (r =0.906, p <0.05). Considering the short 
urinary collection interval (0-40 min) and the usual time lag in drug elimina- 
tion from the bladder, it is not surprising that the initial incremental renal 
clearance is somewhat 10w. This observation for patient EH and the 
relationship between corrected renal clearance of furosemide and the 
percent free in plasma for all of the kidney transplant patients (Fig. 4) 
suggest that plasma protein binding plays a significant role in the renal 
clearance of furosemide. A positive correlation was also observed between 
the nonrenal clearance of furosemide and the percent f ree  in plasma 
(r = 0.841, p <0.02). However, since the changes in both the renal and 
nonrenal clearances of furosemide were proportional to percent free of 
drug, no significant correlation was observed between the fraction of the 
dose excreted in the urine unchanged and percent free of furosemide in 
the kidney transplant patients (Fig. 5; r = -0.106, p > 0.50). 
It is interesting to note that three out of the five kidney transplant 
patients designated as responders were concomitantly taking sulfisoxazole 
with furosemide. However, it is doubtful that this drug interaction was a 
factor in these patients being more responsive to furosemide treatment. 
Although responder patients on concomitant sulfisoxazole had reduced 
binding of furosemide to plasma proteins, this effect was not translated 
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Fig. 5. Correlation between the fraction of the dose excreted in the urine unchanged 
(FE) and percent free of furosemide in plasma in kidney transplant patients 
(r = -0.106, p >0.50). 
into greater values for fraction of the dose excreted unchanged in the urine 
(compare patients SF, PD, and FR to patients VW and WJ; Table II of 
ref. 19). In fact, responder patient WJ ( K T - )  excreted over 70% of the 
unchanged drug in the urine with a percent free for furosemide of only 1.5 %. 
The large number and wide variety of concomitant drugs received by 
the kidney transplant patients (19) could potentially complicate the inter- 
pretation of the protein binding and renal clearance data. However, when 
one analyzes the percent free data (Tables I and II), the variability (CV%) 
about the mean in each subject is relatively small except for those patients 
receiving concomitant sulfisoxazole therapy (compare CT= 19%, D H =  
13%, LT-- 5%, and WT -- 7% vs. SF = 42%, PD = 32%, and FR = 33%). 
In addition, sulfisoxazole is the only drug that is consistent in the three 
patients showing large intrasubject variability in percent free of furosemide. 
Since plasma samples in each subject were obtained over time when 
concentrations of concomitant drugs would be changing, we believe that 
the potential effects of these other drugs on the parameters reported here 
would be minimal. The substantial variability in percent free exhibited by 
patients S J, PD, and FR is most probably due to changing concentrations 
of both sulfisoxazole and furosemide as a function of time. However, no 
consistent trend in the percent free values was observed. Therefore, the 
data were treated as following linear protein binding. 
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In conclusion,  the present  s tudy has shown that  the b ind ing  of 
furosemide  to p lasma prote ins  is significantly reduced  in k idney  t r ansp lan t  
pat ients  as compared  to heal thy volunteers .  This  b ind ing  is fur ther  reduced  
in those pat ients  concomi tan t ly  on  sulfisoxazole. In  addi t ion,  furosemide  
may exhibit  non l inea r  pro te in  b ind ing  as ev idenced  by pa t ien t  EH.  
A l though  differences may exist in the percen t  free of furosemide  in k idney  
t ransp lan t  pat ients ,  the fract ion of the dose excreted in the ur ine  unc ha nge d  
does not  appear  to be inf luenced by its p ro te in  binding.  
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